Drug Type Recombinant polypeptide, Biosimilar |
Synonyms |
Target |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 3 | CN | 04 Jul 2023 | |
Diabetes Mellitus, Type 2 | Phase 3 | CN | 04 Jul 2023 | |
Myocardial Infarction | Phase 1 | CN | 12 Nov 2022 | |
Myocardial Infarction | Phase 1 | CN | 12 Nov 2022 | |
Stroke | Phase 1 | CN | 12 Nov 2022 | |
Stroke | Phase 1 | CN | 12 Nov 2022 | |
Obesity | IND Approval | CN | 08 Jul 2024 |